Reports Q3 revenue $179.52M, consensus $182.33M. “Pacira (PCRX) delivered another quarter of strong execution across our corporate, clinical, and commercial initiatives, underscoring the momentum behind our 5×30 growth strategy,” said Frank D. Lee, chief executive officer of Pacira BioSciences. “With accelerating topline growth, expanding market access, and meaningful pipeline advancements, including the in-licensing of AMT-143, we believe we are well positioned to expand our leadership in musculoskeletal pain and adjacencies. I’m proud of our team’s continued focus and discipline, which are driving innovation, improving patient outcomes, and creating long-term value for our shareholders.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira concludes patient enrollment in Part A of Phase 2 study of PCRX-201
- Pacira enters exclusive license, collaboration agreement with AmacaThera
- Pacira presents updated three-year results of PCRX-201
- Pacira (PCRX) Q3 Earnings Cheat Sheet
- Pacira’s Pediatric Analgesia Study: A Potential Game-Changer for Postoperative Pain Management